Related references
Note: Only part of the references are listed.Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
M. Vagberg et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
Lenka Novakova et al.
JOURNAL OF NEUROCHEMISTRY (2017)
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
Lenka Novakova et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
Jens Kuhle et al.
NEUROLOGY (2017)
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Lenka Novakova et al.
NEUROLOGY (2017)
Pharmacodynamic effects of daclizumab in the intrathecal compartment
Mika Komori et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis
A. Traboulsee et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2016)
No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy
Alfredo Damasceno et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis
Rikke Ratzer et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy
Alfredo Damasceno et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis
Rikke Ratzer et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions
I. -K. Penner
ACTA NEUROLOGICA SCANDINAVICA (2016)
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Jens Kuhle et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Multiple sclerosis, a treatable disease
A. Doshi et al.
CLINICAL MEDICINE (2016)
The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration
Sofia Anastasiadou et al.
EXPERIMENTAL NEUROLOGY (2016)
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis
Joachim Burman et al.
JOURNAL OF NEUROIMMUNOLOGY (2016)
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
Massimo Filippi et al.
LANCET NEUROLOGY (2016)
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Plasma neurofilament light chain predicts progression in progressive supranuclear palsy
Julio C. Rojas et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
Magnus Gisslen et al.
EBIOMEDICINE (2016)
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
Joakim Bergman et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury
Eduardo Martinez-Morillo et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2015)
Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis
S. Modvig et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
J. Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
M. Alba Mane Martinez et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
EVIDENCE-BASED GUIDELINES MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients
Mike P. Wattjes et al.
NATURE REVIEWS NEUROLOGY (2015)
Exploring the origins of grey matter damage in multiple sclerosis
Massimiliano Calabrese et al.
NATURE REVIEWS NEUROSCIENCE (2015)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Jens Kuhle et al.
NEUROLOGY (2015)
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Dalia L. Rotstein et al.
JAMA NEUROLOGY (2015)
Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis
S. Modvig et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
J. Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
M. Alba Mane Martinez et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Disability in Multiple Sclerosis
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2014)
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2014)
Biomarkers for Multiple Sclerosis
Ryo Tomioka et al.
INTERNAL MEDICINE (2014)
The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA
Marleen J. A. Koel-Simmelink et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment
Clas Malmestrom et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
Body fluid biomarkers in multiple sclerosis
Manuel Comabella et al.
LANCET NEUROLOGY (2014)
Cortical lesion load correlates with diffuse injury of multiple sclerosis normal appearing white matter
Niraj Mistry et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis
Antonio Giorgio et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Markus Axelsson et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes
Raquel Mitjana et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Manuel A. Friese et al.
NATURE REVIEWS NEUROLOGY (2014)
Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial
Jeppe Romme Christensen et al.
NEUROLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Disease Activity Free Status A New End Point for a New Era in Multiple Sclerosis Clinical Research?
Carolyn J. Bevan et al.
JAMA NEUROLOGY (2014)
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis
J. Kuhle et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis
Alberto Gajofatto et al.
DISEASE MARKERS (2013)
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis
Markus Axelsson et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients
Marcel P. Stoop et al.
JOURNAL OF PROTEOME RESEARCH (2013)
Pathology and disease mechanisms in different stages of multiple sclerosis
Hans Lassmann
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis
Violaine K. Harris et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
Charlotte Teunissen et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
A comparative study of CSF neurofilament light and heavy chain protein in MS
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Johanna Gaiottino et al.
PLOS ONE (2013)
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Graziella Filippini et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Association between pathological and MRI findings in multiple sclerosis
Massimo Filippi et al.
LANCET NEUROLOGY (2012)
Measurement and clinical effect of grey matter pathology in multiple sclerosis
Jeroen J. G. Geurts et al.
LANCET NEUROLOGY (2012)
Neurofilaments as biomarkers in multiple sclerosis
Charlotte E. Teunissen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Disease activity free status in MS
Fred D. Lublin
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
The Neurofilament Light Chain is Not Stable in Vitro
Marleen J. A. Koel-Simmelink et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
M. Axelsson et al.
JOURNAL OF NEUROLOGY (2011)
Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis
Jorge Correale et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis
Lars Bornsen et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
J. Kuhle et al.
NEUROLOGY (2011)
Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood
Martin Lundberg et al.
NUCLEIC ACIDS RESEARCH (2011)
The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
Antonio Scalfari et al.
BRAIN (2010)
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
Manuel Comabella et al.
BRAIN (2010)
Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland
Norman Putzki et al.
EUROPEAN NEUROLOGY (2010)
In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases
Dafna Bonneh-Barkay et al.
JOURNAL OF NEUROINFLAMMATION (2010)
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
J. Mellergard et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Neurofilament light as a prognostic marker in multiple sclerosis
Jonatan Salzer et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations
David M. Rissin et al.
NATURE BIOTECHNOLOGY (2010)
Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis
Violaine K. Harris et al.
NEUROBIOLOGY OF DISEASE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
N. Putzki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
M. Khademi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova et al.
LANCET NEUROLOGY (2009)
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
F. Sellebjerg et al.
NEUROLOGY (2009)
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
C. E. Teunissen et al.
NEUROLOGY (2009)
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
C. E. Teunissen et al.
NEUROLOGY (2009)
Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis
Manjit Braitch et al.
ARCHIVES OF NEUROLOGY (2008)
Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis
Soheli A. Chowdhury et al.
ARCHIVES OF NEUROLOGY (2008)
Lymphoid chemokines in chronic neuroinflammation
Francesca Aloisi et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Clinical markers of therapeutic response to disease modifying drugs
Carlo Pozzilli et al.
NEUROLOGICAL SCIENCES (2008)
Ultrasensitive flow-based immunoassays using single-molecule counting
John Todd et al.
CLINICAL CHEMISTRY (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natural history of multiple sclerosis: a unifying concept
C Confavreux et al.
BRAIN (2006)
Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
A Petzold
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
A Petzold et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Neurofilament and glial fibrillary acidic protein in multiple sclerosis
N Norgren et al.
NEUROLOGY (2004)
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
C Malmeström et al.
NEUROLOGY (2003)
Elevated neurofilament levels in neurological
N Norgren et al.
BRAIN RESEARCH (2003)
Spinal-cord MRI in multiple sclerosis
G Lycklama et al.
LANCET NEUROLOGY (2003)
Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir
J Lycke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Cognitive dysfunction in early-onset multiple sclerosis - A reappraisal after 10 years
MP Amato et al.
ARCHIVES OF NEUROLOGY (2001)
A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis
NC Silver et al.
JOURNAL OF NEUROLOGY (2001)
Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000)
LF Eng et al.
NEUROCHEMICAL RESEARCH (2000)
Share Paper
